Evidence map›Paper›PMID 26066920›Full record

ArticleAmerican journal of public health2015

Decreasing Hepatitis C Incidence Among a Population With Repeated Tests: British Columbia, Canada, 1993-2011.

Margot Kuo, Naveed Z Janjua, Ann N Burchell, Jane A Buxton, Mel Krajden, Mark Gilbert

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of public health, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.1field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 20 citations in OpenAlex.

  1. Article
  2. Trends in new hepatitis C virus infections among repeat blood donors - Georgia, 2017-2023.Transfusion clinique et biologique : journal de la Societe francaise de transfusion sanguine · 2025
    Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Margot KuoAt the time of the writing, all of the authors were with the British Columbia Centre for Disease Control, Vancouver, Canada. Ann N. Burchell is with the Ontario HIV Treatment Network, Toronto, Canada.
Naveed Z JanjuaAt the time of the writing, all of the authors were with the British Columbia Centre for Disease Control, Vancouver, Canada. Ann N. Burchell is with the Ontario HIV Treatment Network, Toronto, Canada.
Ann N BurchellAt the time of the writing, all of the authors were with the British Columbia Centre for Disease Control, Vancouver, Canada. Ann N. Burchell is with the Ontario HIV Treatment Network, Toronto, Canada.
Jane A BuxtonAt the time of the writing, all of the authors were with the British Columbia Centre for Disease Control, Vancouver, Canada. Ann N. Burchell is with the Ontario HIV Treatment Network, Toronto, Canada.
Mel KrajdenAt the time of the writing, all of the authors were with the British Columbia Centre for Disease Control, Vancouver, Canada. Ann N. Burchell is with the Ontario HIV Treatment Network, Toronto, Canada.
Mark GilbertAt the time of the writing, all of the authors were with the British Columbia Centre for Disease Control, Vancouver, Canada. Ann N. Burchell is with the Ontario HIV Treatment Network, Toronto, Canada.
Ontario HIV Treatment Network · CA

Funding

Canadian Institutes of Health Research
6 · The paper itself

Abstract

objectivesWe estimated HCV incidence among individuals who repeatedly underwent anti-HCV testing.

methodsWe studied HCV-negative individuals who had at least 2 tests between April 1992 and September 2012 in British Columbia, Canada. We calculated incidence as the number of new infections per 100 person-years at risk.

resultsFrom 1992 to 2012, 323 598 individuals who persistently tested negative and 7490 HCV seroconverters contributed 1 774 262 person-years of observation time. Incidence rates ranged from 2.66 infections per 100 person-years (95% confidence interval [CI] = 2.07, 3.35) in 1993 to 0.25 infections per 100 person-years (95% CI = 0.21, 0.29) in 2011. Rates declined sharply in the 1990s and declined more gradually in the 2000s. Incidence declined with age; highest incidence rates were among those aged 15 to 24 years. Incidence among male repeat testers exceeded that of female repeat testers across all years, although the gap narrowed over time.

conclusionsAddictions treatment, harm reduction, prevention education, and novel initiatives to remove barriers in health infrastructure need to be intensified for those who inject drugs, particularly men and younger persons.

Indexed as

AdolescentAdultAge FactorsBritish ColumbiaFemaleHepatitis CHumansIncidenceMaleMiddle AgedSerologic TestsSex FactorsYoung Adult

Identifiers

PMID26066920
PMCPMC4504305
OpenAlexW2121796036

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.